🟢 Outlook Therapeutics is trading 11.39% up in pre-market after pricing a $55 million stock-and-warrant offering

Outlook Therapeutics is trading 11.39% up at $0.99 after announcing pricing for a $55.0 million public offering of common stock and warrants.

• Units are priced at $0.99 per share and warrant, with warrants exercisable at $1.10.
• Closing is expected on August 14, 2026.
• The financing addresses liquidity concerns and supports LYTENAVA commercialization; third-quarter results and a corporate update are scheduled for 8:30 a.m. EDT.